Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:activities |
lowers blood glucose levels
|
| gptkbp:appointed_by |
subcutaneous injection
|
| gptkbp:approves |
1923
|
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Humulin_R
Novolin R |
| gptkbp:clinical_trial |
hyperglycemia
ketoacidosis mealtime insulin basal insulin in some regimens studied for various diabetes types |
| gptkbp:contraindication |
hypoglycemia
hypersensitivity to insulin |
| gptkbp:developed_by |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:duration |
5 to 8 hours
|
| gptkbp:education |
proper injection technique
recognize hypoglycemia symptoms dietary considerations |
| gptkbp:form |
pens
vials |
| gptkbp:formulation |
liquid solution
human insulin |
| gptkbp:highest_point |
2 to 3 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
regular insulin
|
| gptkbp:interacts_with |
gptkb:beer
beta-blockers thiazide diuretics |
| gptkbp:is_compared_to |
faster onset than long-acting insulin
shorter duration than intermediate-acting insulin |
| gptkbp:is_monitored_by |
blood glucose levels
Hb A1c |
| gptkbp:is_used_for |
gptkb:Company
|
| gptkbp:manager |
intravenous
subcutaneous |
| gptkbp:packaging |
pre-filled pens
multi-dose vials |
| gptkbp:pharmacokinetics |
excreted in urine
metabolized in the liver absorption varies by injection site |
| gptkbp:premiered_on |
30 minutes
|
| gptkbp:price |
varies by location and insurance
|
| gptkbp:provides_information_on |
recommended for type 1 diabetes
used in type 2 diabetes when needed |
| gptkbp:safety_features |
generally safe when used as directed
|
| gptkbp:side_effect |
gptkb:lipodystrophy
allergic reactions weight gain hypoglycemia |
| gptkbp:social_structure |
C256 H383 N65 O77 S6
|
| gptkbp:storage |
refrigerated
|
| gptkbp:type |
short-acting insulin
|
| gptkbp:weight |
5808.4 g/mol
|
| gptkbp:bfsParent |
gptkb:insulin_analogs
|
| gptkbp:bfsLayer |
5
|